Fig. 5From: Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphomaKaplan–Meier curves of progression-free and overall survival in pSTAT3-negative diffuse large B cell lymphoma patients treated with R-CHOP. Survival analysis for progression-free survival (PFS) according to PD-L1i in pSTAT3-negative R-CHOP treated subset (n = 57) (a) and survival analysis for overall survival in pSTAT3-negative R-CHOP treated subset (n = 57) (b). * I: non-malignant immune cellBack to article page